A costly cancer therapy may get a manufacturing rethink
CAR T-cell therapy is one of the most powerful tools in modern cancer treatment, but it remains limited by cost and production time. A new approach using 3D-printed structures that mimic human lymph nodes could help change that by improving how engineered immune cells are activated and expanded before they are infused back into patients.
The promise matters because access remains narrow. According to the source text, a single round of CAR T-cell therapy can cost more than £280,000, and the overall manufacturing process can take about a month. For very ill patients, that delay is not trivial. Some deteriorate before treatment is ready.
How CAR T cells are usually made
In standard CAR T therapy, clinicians collect T-cells from a patient’s blood and genetically engineer them to recognize cancer cells. The cells are commonly mixed with tiny beads that stimulate proliferation and with a harmless virus that delivers genetic instructions for a cancer-targeting chimeric antigen receptor, or CAR.
The process works, but it is imperfect. Typically, only 30 to 70 percent of T-cells are successfully reprogrammed, with better outcomes linked to higher proportions of engineered cells. After that, the cells are multiplied for weeks before being returned to the patient.
What the 3D-printed approach changes
The new work, led by Judit Guasch Camell at the Materials Science Institute of Barcelona, uses 3D printing to create a gel structure that resembles the texture and arrangement of human lymph nodes. That design choice is not cosmetic. Lymph nodes are where T-cells are naturally activated when the immune system recognizes a threat, and earlier studies suggest T-cells respond to the physical properties of that environment.
By better imitating the place where T-cells are biologically primed to activate and proliferate, the printed structures could improve efficiency during manufacturing. The goal is not simply to make the process more elegant. It is to produce useful CAR T cells faster and at lower cost.
Why this could widen access
Experts quoted in the source text underscore the global access problem. CAR T therapy is highly effective for some cancers, but its price makes it available mainly in wealthier countries. If manufacturing becomes cheaper, more reliable, and faster, the treatment could reach more hospitals and more patients.
That time factor may be just as important as cost. David Coe of CoED Biosciences, who was not involved in the research, notes in the source text that some patients may never receive treatment because of how long production can take. Any platform that compresses that timeline could have direct clinical value.
Still early, but strategically important
This is not yet a story about immediate replacement of existing CAR T manufacturing. It is a story about process innovation in one of biomedicine’s most resource-intensive therapies. Manufacturing constraints often determine whether a breakthrough remains elite or becomes widespread. In cell therapy, that bottleneck is especially severe because the product is individualized, technically demanding, and highly time-sensitive.
The 3D-printed lymph-node concept targets that bottleneck directly. If the approach improves activation and expansion in a reproducible way, it could help turn CAR T production from a slow and expensive bespoke process into something more scalable.
Why researchers are watching this
- CAR T therapy can cost more than £280,000 per treatment round.
- Current manufacturing can take about a month, which is too long for some patients.
- 3D-printed lymph-node-like structures may improve T-cell activation and proliferation.
For cell therapy, the science of killing cancer cells is only half the battle. The other half is manufacturing those cells quickly enough, cheaply enough, and consistently enough to reach the people who need them. This work is aimed squarely at that problem.
This article is based on reporting by New Scientist. Read the original article.
Originally published on newscientist.com
